Rapid Medical’s Tigertriever 25 Cleared by FDA to Treat LVO Stroke

April 16, 2026—Rapid Medical announced FDA clearance of the Tigertriever 25 thrombectomy device.

Stereotaxis to Acquire Robocath

April 15, 2026–Stereotaxis, a St. Louis, Missouri–based company focused on robotics for endovascular intervention, announced that it has entered into a definitive agreement to acquire Robocath.

Medtronic’s IN.PACT AV Access Postapproval Study Reports 12-Month Outcomes

April 15, 2026—Medtronic announced that 12-month findings from the IN.PACT AV Access postapproval study of the company’s In.Pact AV drug-coated balloon (DCB) demonstrated the device’s safety and effectiveness in the treatment of arteriovenous (AV) fistula stenoses in patients with end-stage renal disease (ESRD) on dialysis.

Data Presented for Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP Therapy Platform

April 14, 2026—RenovoRx, Inc., which is developing targeted oncology therapies and commercializing its FDA-cleared RenovoCath drug-delivery device, announced findings on the effectiveness of local, targeted intra-arterial chemotherapy administration using the company’s transarterial microperfusion therapy (TAMP) platform.

Imperative Care Initiates ADAPT 2.0 Study of Zoom System for Acute Ischemic Stroke

April 14, 2026—Imperative Care announced that the initial patients have been enrolled in the ADAPT 2.0 clinical study of continuous dual aspiration using the company’s Zoom system for acute ischemic stroke.

Reflow’s Spur Stent System Evaluated for CLTI in 12-Month DEEPER REVEAL Data

April 13, 2026—Reflow Medical, Inc. announced 12-month results from the DEEPER REVEAL clinical trial.

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

C-TRACT Evaluates Endovascular Therapy to Treat Postthrombotic Syndrome After DVT 

April 13, 2026—The Society of Interventional Radiology (SIR) announced results from the C-TRACT study, which is investigating the treatment of postthrombotic syndrome (PTS) after deep vein thrombosis (DVT).